Condition: Arrhythmogenic Right Ventricular Dysplasia · Sponsor: University Hospital, Toulouse
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
This description comes directly from the study's public registry record.
Philippe MAURY, MD · 5 61 32 34 70 · maury.p@chu-toulouse.fr
Maxime BENEYTO · beneyto.m@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| Toulouse University Hospital Center | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05209776